Drug Database
Back to search

Belgium· BE-AMP-SAM381866-00

Esmocard 2500 mg

A esmolol product containing esmolol hydrochloride, registered in Belgium by Orpha-Devel Handels und Vertriebs. The same ATC class is registered in 16 of our 19 countries.

ATC C07AB09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedEsmocard 2500 mgATCC07AB09REGISTER NO.BE-AMP-SAM381866-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about esmolol hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Esmolol is registered in 16 of 19 countries.

Countries holding a registration under ATC C07AB09 (esmolol), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search esmolol products by name

Esmolol · ATC C07AB09

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Esmolol Hydrochloride
Manufacturer
Orpha-Devel Handels und Vertriebs
Country
Belgium (BE)
ATC code
C07AB09
ATC class
Esmolol
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    7714827
  • be_apb
    3377298

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

196 interactions on record for esmolol.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check esmolol against other medicinesHow interaction checks work

Esmolol · interactions on record

196 records

  • 11 severe
  • 139 moderate
  • 8 minor

Most severe, free to view

  • DolasetronA04AA04severe
  • TheophyllinC01EB28severe
  • CeritinibL01ED02severe
  • CeritinibL01XE28severe

38 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Esmolol in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All esmolol products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Austria · Brevibloc, Esmolol Amomed
  • Cyprus · Brevibloc, Esmobeta
  • Czechia · Esmocard, Esmocard Lyo
  • Germany · Brevibloc, Esmocard
  • Denmark · Brevibloc
  • Spain · Brevibloc, Esmolol Aurovitas
  • Finland · Brevibloc
  • France · Brevibloc, Esmocard
  • United Kingdom (Northern Ireland) · Brevibloc Premixed, Esmolol Hikma Farmacêutica (Portugal)
  • Greece · Brevibloc, Esmobeta
  • Croatia · Esmocard
  • Ireland · Brevibloc Premixed
  • Italy · Brevibloc, Esmocard
  • Luxembourg · Brevibloc
  • Malta · Brevibloc Premixed
  • Netherlands · Brevibloc, Esmolol Hcl Hikma
  • Norway · Brevibloc
  • Portugal · Brevibloc, Esmolol Eugia
  • Sweden · Brevibloc
  • Slovenia · Esmocard, Esmocard Lyo
  • Slovakia · Esmocard, Esmocard Lyo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6772c0b5-d7af-4d3f-8c4a-53e3efc4545a
GET /v1/drugs/6772c0b5-d7af-4d3f-8c4a-53e3efc4545a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for concentrate for solution for infusion",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Esmocard 2500 mg",
  "name_fr": "Esmocard 2500 mg",
  "name_nl": "Esmocard 2500 mg",
  "amp_code": "SAM381866-00",
  "strengths": [
    "2500.0000",
    "2500.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Esmolol Hydrochloride"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Esmolol",
  "authorisation_numbers": [
    "BE381866"
  ]
}
API referenceMCP serverPlans

See everything about esmolol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console